Percutaneous Mechanical Circulatory Support Devices Market to 2025 – Global Analysis and Forecasts by Product, Application, End-user

The global percutaneous mechanical circulatory support devices market accounted to US$ 1,188.2 Mn in 2017 and is expected to grow at a CAGR of 12.3% during the forecast period 2018 - 2025, to account to US$  2,977.8 Mn by 2025. 

Asia-Pacific was the leading geographic market and it is anticipated to be the highest revenue contributor throughout the forecast period.  Higher concentration of small scale industries in the developing countries like India and China, is expected to fuel percutaneous mechanical circulatory support devices market in this region.

Get Sample Copy Of [email protected] https://www.theinsightpartners.com/sample/TIPRE00003194/

Strategic Insights:

Product approval and acquisition were observed as the most adopted strategy in global percutaneous mechanical circulatory support devices industry. Few of the recent product approvals and acquisitions are listed below:

2018: Abbott received approval for the HeartMate 3 Left Ventricular Assist Device (LVAD) as a destination therapy for people living with advanced heart failure. With the approval, physicians can now offer the HeartMate 3 system to patients not eligible for a transplant who will live with their device for the rest of their lives.

2018: Teleflex Incorporated received FDA 510 (k) clearance for its Arrow AC3 Optimus intra-aortic balloon pump. The device is designed to help weakened hearts pump blood and can deliver IABP therapy to a broad range of patients, including candidates who had previously not been considered for IABP therapy.

2018: Medtronic completed acquisition of HeartWare International, Inc., a leading innovator of less-invasive, miniaturized, mechanical circulatory support technologies (MCS) for treating patients with advanced heart failure.

Company Profiles:

  • Abbott
  • Medtronic
  • Getinge AB
  • Teleflex Incorporated
  • LivaNova PLC
  • ABIOMED
  • EUROSETS
  • Berlin Heart
  • Jarvik Heart, Inc.
  • CardioBridge GmbH

Market Insights :

Shortage of heart donors are expected to boost the market growth over the years

Patients with advanced heart failure have a poor prognosis and heart transplant is still the best treatment option. However, the scarcity of donors, long waiting times, and an increasing number of unstable patients have favored the development of mechanical circulatory support. Moreover, according to the Heart Failure Society of America, nearly 5.7 million Americans are suffering from heart failure. The data also suggests that almost 1.4 million persons with CHF are under 60 years of age. Thus, the solution to this shortage of heart donors served by the temporarily used percutaneous mechanical circulatory support devices that are also helpful in long-term support for patients suffering with heart failures are likely to be adopted at higher rates in the coming years.

Surge of regional business diversities

Business diversity is one of the major concerns hovering around the globalization of any organization. Geographies around the globe are characterized by high regional diversities with respect to various facts such as demands of the customer, disposable incomes of the consumer, Governmental legislations in the region, the percentage of the youth population, percentage of literacy in the region, and some cultural deviations. Altogether, these factors require a deep and focused study before for tapping the new market. Hence, hiring personnel for performing the market has become a necessity for small and large organizations.

Product Insights

The global percutaneous mechanical circulatory support devices market by product was led by intra-aortic balloon pumps segment. Rest of the products considered in the percutaneous mechanical circulatory support devices market include VA-extracorporeal membrane oxygenation and short-term ventricular assist devices. In 2017, the intra-aortic balloon pumps segment held a largest market share of 42.0% of the percutaneous mechanical circulatory support devices market, by product. This segment is also expected to dominate the market in 2025, by product as these systems are associated with better outcomes, rare complication rates and low mortality rates.

End User Insights

The percutaneous mechanical circulatory support devices market by end user is segmented into hospitals, ambulatory surgical centers and others. Others sub-segment includes cardiac centers and specialized clinics among others. The listed companies are witnessing the need for technological advancements, operational changes, improvement of operational efficiency, and enhanced decision making. This has propelled the market for percutaneous mechanical circulatory support devices for the listed companies.

Speak With Industrial [email protected] https://www.theinsightpartners.com/inquiry/TIPRE00003194/

 

By Product

  • Intra-Aortic Balloon Pumps
  • VA-Extracorporeal Membrane Oxygenation (ECMO)
    • Oxygenators
    • Short-term Ventricular Assist Devices
    • Impella
    • TandemHeart

By End User

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • UK
    • Rest of Europe
  • Asia Pacific (APAC)
    • China
    • India
    • Japan
    • Rest of APAC
  • Middle East & Africa (MEA)
    • Saudi Arabia
    • South Africa
    • UAE
    • Rest of MEA
  • South America (SAM)
    • Brazil
    • Rest of SAM

Get Customization On [email protected] https://www.theinsightpartners.com/discount/TIPRE00003194/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services.

We are committed to providing highest quality research and consulting services to our customers. We help our clients understand key market trends, identify opportunities, and make informed decisions by providing market research solutions at an affordable cost.

Contact us:

The Insight partners,

Phone: +1-646-491-9876

Email: [email protected]

Posted by on Thursday June 20 2019, 11:20 AM EDT. All trademarks acknowledged. Filed under Biotechnology, Diagnostics, Healthcare, Life Sciences, Medical Devices, Pharmaceuticals. Comments and Trackbacks closed. Follow responses: RSS 2.0

Comments are closed

News Categories

Featured Press Releases

Latest News

Log in